Smith, JW, Barlas, RS, Mamas, MA ORCID: https://orcid.org/0000-0001-9241-8890, Boekholdt, SM, Mallat, Z, Luben, RN, Wareham, NJ, Khaw, K-T and Myint, PK (2021) Association between serum secretory phospholipase A2 and risk of ischemic stroke. European Journal of Neurology.

[img] Text
ene.15004.pdf - Accepted Version
Restricted to Repository staff only until 3 July 2022.
Available under License Creative Commons Attribution Non-commercial.

Download (7MB)

Abstract

BACKGROUND AND PURPOSE: Previous literature has demonstrated an association between high serum levels of type-II secretory phospholipase A2 (sPLA2) concentration and an increased risk of coronary artery disease. However, such association has not been established in terms of ischemic stroke risk. We aimed to evaluate the association between both sPLA2 concentration and activity as continuous variables with risk of future ischemic stroke. METHODS: We conducted a nested case-control study using data from the European Prospective Investigation into Cancer - Norfolk study. Cases (n=145) in the current study were participants who developed ischemic stroke during follow-up, with controls (n=290) matched in a 2:1 ratio based on age and sex. Statistical analyses were performed using SPSS (version 25.0, Chicago, Ill) software. Logistic regression was used to determine odds ratios (OR) and corresponding 95% confidence intervals (95% CIs) for ischemic stroke. RESULTS: After adjusting for a wide array of cardiovascular confounders, sPLA2 activity was found to be associated with an increased risk of ischemic stroke using both multiple imputations with chained equations and complete case analysis: OR 1.20 (95% CI: 1.01-1.43) and OR 1.23 (95% CI: 1.01 -1.49), respectively. However, sPLA2 concentration was not found to be associated with increased risk of ischemic stroke. CONCLUSIONS: The activity of sPLA2, but not sPLA2 concentration, is associated with an increased risk of future ischemic stroke. This finding may be significant in risk group stratification, allowing targeted prophylactic treatment, or the development of novel therapeutic agents.

Item Type: Article
Additional Information: The final version of this accepted manuscript and all relevant information related to it, including copyrights, can be found online at; https://onlinelibrary.wiley.com/doi/10.1111/ene.15004
Subjects: R Medicine > R Medicine (General)
R Medicine > RA Public aspects of medicine
Divisions: Faculty of Medicine and Health Sciences > School of Medicine
Related URLs:
Depositing User: Symplectic
Date Deposited: 12 Aug 2021 10:49
Last Modified: 12 Aug 2021 10:49
URI: https://eprints.keele.ac.uk/id/eprint/9863

Actions (login required)

View Item View Item